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Further studies are needed to determine the long-term eﬃcacy and the
optimal treatment schedule.
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Purpose: The hand is the most commonly affected site in osteoarthritis
(OA). First carpometacarpal (CMC) and proximal interphalangeal (PIP) joint
involvement often leads to pain, progressive loss of hand function and
deformity. Synovitis is a common ﬁnding and is likely to be one cause of
pain in this group. A specialist hand OA clinic was set up in 2006 with
the aim of delivering high quality care based on the EULAR guidelines.
The role of intra-articular steroid in these patients remains controversial,
and we therefore examined the outcomes of 2 groups of patients from
the clinic who received either ﬁrst CMC or PIP joint injections as part of
their treatment. We hypothesised that CMC joint injection would be more
effective than PIP joint injection, and that presence of inﬂammation (high
pain scores, raised CRP or presence of synovial power doppler signal on
ultrasound) would predict clinical response.
Methods: Sequential patients fulﬁlling ACR criteria for OA seen between
October 2006 and October 2009 who received corticosteroid joint injection
were followed prospectively. Clinical and hand therapy assessment, and
ultrasound assessment for those with PIP joint disease was carried out at
baseline. All patients were given education and an individualised treatment
programme including joint protection and exercises, appropriate splinting
and analgesics review. Worst pain score in the preceding week for the
intervention joint (0-10) was recorded immediately prior to the injection
and at later review. Range of joint motion, joint circumference and Jamar
grip strength were recorded prior to injection, and at review. Patient
subjective pain response to injection at 4 weeks (none, partial, good) was
also recorded retrospectively.
Results: 65 new patients were seen in the clinic during this time. Of
these, 15 patients received at least one CMC joint injection and 15 patients
received at least one PIP joint injection. 24 of these 30 patients were
female. The mean ages of the CMC and PIP group were 62 and 70 years
respectively. In the CMC joint group, 22 different joints were injected. The
mean time to assessment following injection was 91 days (range 35-154).
After 13 procedures, a good response was reported to injection (59%).
In a further 7, there was a partial response (32%). 3 patients required
subsequent re-injection of at least one CMC joint, and 2 patients proceeded
to surgery during subsequent follow-up. 1 patient was lost to follow-up.
In the PIP joint group, 23 different joints were injected. The mean time
to assessment following injection was 130 days (range 49-210). A good
response to injection was reported after 14 procedures (61%) with a further
6 resulting in a partial response (26%). On average, 1 point reduction on the
pain scale, 7 degrees of increased range of motion, a 1 mm decrease in joint
circumference, and 1.3 kg improvement in grip strength were measured at
review, although data was not available for all patients. A high baseline
pain score, raised CRP or power doppler signal evident on ultrasound were
not seen more frequently in those with a good response to injection in
either group (Table 1).
Table 1. Characteristics of patients receiving CMC or PIP joint injections, by response
Joint injected CMC joint PIP joint
Good Partial/no/unknown Good Partial/no/unknown
response response response response
Total procedures n, (%) 13 (59) 9 (41) 14 (61) 9 (39)
Mean baseline pain score
(0-10) 8.7 8.5 6.5 7.0
CRP>5 n, (%) 4 (31) 3 (33) 3 (21) 6 (67)
Power doppler signal
evident at baseline – – 8 (57) 5 (56)
Conclusions: Short-term good or partial responses to either CMC or PIP
joint injection are more common in our experience than in other reports
(91% and 87% respectively). It appears that some improvement in objective
parameters in the PIP joint group is present at a mean interval of 4 months.
Our data support previous observations that many patients have synovial
inﬂammation evident on ultrasound. However, the presence of high pain
scores or biochemical or ultrasonographic inﬂammation did not appear to
predict response to corticosteroid injection, although a controlled study
would be required to accurately assess this. This was an observational
study and the effects of injection cannot be separated from the effects
of other interventions such as education, exercise and splinting. However,
our data support the use of joint injection as part of a multi-disciplinary
treatment programme for those with symptomatic hand osteoarthritis.
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Purpose: Hyaluronic acid (HA) injections are safe but costly interventions
that are widely used for knee osteoarthritis (OA) despite views that evi-
dence for their eﬃcacy is weak. Indeed, systematic reviews have generated
conﬂicting results, hampered by low quality of trials available for meta-
analysis and possible conﬂicts of interest. However, these meta-analyses
did not evaluate the post-injection trajectory of its therapeutic effect,
an aspect that would provide meaningful insight into its effectiveness,
nor did they beneﬁt from the extent of data now available. Therefore,
we performed a meta-analysis using fully current data to evaluate the
magnitude of effect of hyaluronic acid at speciﬁed intervals post-treatment
with adjustment for trial quality indicators.
Methods: We searched Medline, EMBASE, CINAHL, BIOSIS, Cochrane
database, Web of Science and Google Scholar from inception to March
2010 for human randomized clinical trials comparing hyaluronic acid vs.
placebo for knee OA. We hand searched review articles, manuscripts and
medical journal supplements, and contacted authors for unpublished data.
Two reviewers independently assessed the quality of each trial and ex-
tracted means and variances for pain, function and stiffness. We computed
effect sizes for mean change from baseline to weeks 4, 8, 12, 16, 20 and
24 using Hedges’ g statistic. Effect sizes were pooled using random effects
model. We deﬁned "high quality trials" as those with N>100 also reporting
intent-to-treat analysis, blinding, and allocation concealment. We per-
formed sensitivity analyses by pooling high quality trials and multivariate
analyses adjusting for correlation between time points.
Results: The 54 eligible trials published during 1983 - 2009 included 7545
participants with age range 45-72 yrs. The proportion of women ranged
28% - 100%. There were 16 high quality trials (n = 3176) and 8 were
unpublished (n = 963). Industry aﬃliation was present in 36 trials and
unclear in 17; 1 trial was independent. The effect size for pain favored
hyaluronic acid by week 4 (0.31; 95% CI 0.17, 0.45), reaching a peak at
week 8 (0.46; 0.28, 0.65), and then trending downwards, with a residual
detectable effect at week 24 (0.21; 0.10, 0.31) (Table 1). This therapeutic
trajectory was consistent among the subset of high quality trials and on
multivariate analysis adjusting for correlation between time points. The
effect on function and stiffness also showed similar trajectory.
Table 1. Pooled effect sizes (95% CI)
Wk Pain (All Trials) Pain (High Quality) Function Stiffness
N Effect Size N Effect Size N Effect Size N Effect Size
4 44 0.31(0.17,0.45) 14 0.27(0.04,0.49) 10 0.48(0.12,0.84) 8 0.64(0.25,1.04)
8 26 0.46(0.28,0.65) 7 0.34(0.02,0.67) 4 0.41(-0.07,0.89) 4 0.28(-0.08,0.63)
12 31 0.25(0.15,0.36) 12 0.29(0.13,0.45) 11 0.16(-0.04,0.36) 9 0.23(0.01,0.45)
16 15 0.20(0.11,0.30) 8 0.22(0.09,0.36) 2 0.23(0.03,0.44) 2 0.20(-0.01,0.40)
24 20 0.21(0.10,0.31) 6 0.20(0.03,0.37) 11 0.14(-0.02,0.30) 10 0.11(-0.10,0.31)
Wk = Weeks, N = Number of trials, CI = Conﬁdence Interval.
Conclusions: This meta-analysis highlights the therapeutic trajectory of
intra-articular hyaluronic acid for knee OA pain over six months following
the intervention. With this additional perspective, we are able to infer
that intra-articular hyaluronic acid is eﬃcacious by 4 weeks, reaches its
peak effectiveness at 8 weeks and exerts a residual detectable at 24 weeks
(Figure 1). On the other hand, the peak effect size (0.46; 0.28, 0.65), is
greater than the published effects from other OA analgesics. The magnitude
of effect is modest, and exceeds a minimally clinically signiﬁcant thresh-
old. Thus, its properties could have utility for certain clinical situations,
